Survival and time to surgery, chemotherapy for patients with breast cancer

December 10, 2015

The association between survival and the time to surgery and chemotherapy for patients with breast cancer is examined in two original investigations published by JAMA Oncology, along with a related editorial and an audio interview with the authors.

In the first study, Mariana Chavez-MacGregor, M.D., M.Sc., of the University of Texas MD Anderson Cancer Center, Houston, and coauthors, analyzed data from 24,843 patients with invasive breast cancer (stages I to III) from the California Cancer Registry to examine the relationship between time to chemotherapy after surgery and overall survival and breast cancer-specific survival. The authors also identified factors associated with a delayed start of chemotherapy.

The median age of the 24,843 patients at diagnosis was 53 and the median time to chemotherapy was 46 days. In the study, 21 percent of patients started chemotherapy within fewer than 31 days; 50 percent between 31 and 60 days after surgery; 19.2 percent between 61 and 90 days; 9.8 percent in 91 or more days after surgery.

The factors associated with delays in time to chemotherapy included low socioeconomic status, breast reconstruction, nonprivate insurance, and being Hispanic or black, according to the study.

Compared with patients who received chemotherapy within 31 days of surgery, the study reports no adverse outcomes were associated with time to chemotherapy of 31 to 90 days of surgery.

However, there was increased risk of worse overall survival and worse breast cancer-specific survival among patients treated with chemotherapy 91 or more days after surgery, the results indicate. The study suggests patients with a time to chemotherapy of 91 or more days had a 34 percent increased risk of overall death and a 27 percent increased risk of death from breast cancer.

For patients with triple-negative breast cancer, 91 or more days to chemotherapy was associated with worse overall and breast cancer-specific survival, according to the study.

The authors note their study is limited by its retrospective nature, which uses historical data.

"Given the results of our analysis, we would suggest that all breast cancer patients that are candidates for adjuvant chemotherapy should receive this treatment within 91 days of surgery or 120 days from diagnosis. Administration of chemotherapy within this frame is feasible in clinical practice under most clinical scenarios, and as medical oncologists, we should make every effort not to delay the initiation of adjuvant chemotherapy. Furthermore, determinants of delay in TTC [time to chemotherapy] were sociodemographic in nature; better understanding and removing barriers to access of care in vulnerable populations should be a priority," the study concludes.

In a second study, Richard J. Bleicher, M.D., of the Fox Chase Cancer Center, Philadelphia, and coauthors looked at the relationship between the time from diagnosis to breast cancer surgery and survival. The authors analyzed patient data from two of the largest cancer databases in the United States. Analysis between the two databases was not done, or warranted, so the authors present both analyses.

Data were analyzed for 95,544 patients (mostly women, average age 75) in the Surveillance, Epidemiology and End Results (SEER)-Medicare database. Of the patients, 77.7 percent had surgery in 30 days or less; 18.3 percent in 31 to 60 days; 2.7 percent in 61 to 90 days; 0.7 percent in 91 to 120 days; and 0.5 percent in 121 to 180 days. The increase in death in all stages of disease for all patients and from all causes was 9 percent for each preoperative time interval increase. While overall survival was lower with each interval of delay increase, the decline was most pronounced in patients with stage I and stage II disease. The risk of death from breast cancer for each 60-day increase in time to surgery was significant for stage I disease, according to the results.

Data also were analyzed for 115,790 patients (nearly all women, average age 60) in the National Cancer Database. Of the patients, 69.5 percent of patients had surgery in 30 days or less; 24.9 percent in 31 to 60 days; 4.1 percent in 61 to 90 days; 1 percent in 91 to 120 days; and 0.5 percent in 121 to 180 days. The added risk of death from all causes for each interval increase in time to surgery was 10 percent for the entire group, and most pronounced for stage I and stage II disease.

The authors acknowledge unmeasured confounders may exist in their study.

"In conclusion, survival outcomes in early-stage breast cancer are affected by the length of the interval between diagnosis and surgery, and efforts to minimize that interval are appropriate. Although the effect on both overall and disease-specific survival remains small, consideration should be given to establishing reasonable and attainable goals for the timing of surgical interventions to afford this population a finite, but clinically relevant, survival benefit," the study concludes.

(JAMA Oncol. Published online December 10, 2015. doi:10.1001/jamaoncol.2015.3856. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: The study includes funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

(JAMA Oncol. Published online December 10, 2015. doi:10.1001/jamaoncol.2015.4508. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: The study includes funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: Timeliness in Breast Cancer Treatment

"The articles published in this issue of JAMA Oncology increase our confidence that avoiding delays in breast cancer care is important to ensuring the best possible outcomes for our patients. ... Few people like standing in line at the supermarket; if retailers can make efforts to minimize customer wait times, so we, too, can make sure that patients are seen and treated as promptly as possible," write Eric P. Winer, M.D., of the Dana-Farber Cancer Institute, Boston, and coauthors in a related editorial.

(JAMA Oncol. Published online December 10, 2015. doi:10.1001/jamaoncol.2015.4506. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
-end-
Media Advisory: To contact corresponding author Mariana Chavez-MacGregor, M.D., M.Sc., call Laura Sussman at 713-745-2457 or email lsussman@mdanderson.org or call Clayton Boldt at 713-792-9518 or email crboldt@mdanderson.org.To contact corresponding author Richard J. Bleicher, M.D., call Amy Merves at 215-280-0810 email Amy.Merves@fccc.edu. To contact corresponding editorial author Eric P. Winer, M.D., call John W. Noble at 617-632-5784 or email JohnW_Noble@dfci.harvard.edu.

To place an electronic embedded link in your story: Links will be live at the embargo time: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.3856;http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.4508;http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.4506

Related material: An author audio interview is available for preview on the For The Media website and will be available when the embargo lifts on the JAMA Oncology website

The JAMA Network Journals

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.